ALPA LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 95 INR | -1.66% |
|
+0.21% | -8.03% |
| Feb. 13 | Alpa Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| Feb. 13 | Alpa Laboratories Limited Announces Reconstitution of Committees | CI |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 815.3 | 560.7 | 291.4 | 757.5 | 1,467 | 1,132 |
| Enterprise Value (EV) 1 | 484.6 | 276.3 | -147.2 | 334.5 | 822.3 | 346.6 |
| P/E ratio | 29.2 x | 70.6 x | 15.7 x | 10.5 x | 10.4 x | 9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.3 x | 0.72 x | 0.34 x | 0.78 x | 1.19 x | 1.22 x |
| EV / Revenue | 0.77 x | 0.35 x | -0.17 x | 0.34 x | 0.67 x | 0.37 x |
| EV / EBITDA | 11.1 x | 20.6 x | -2.51 x | 3.87 x | 3.83 x | 4.28 x |
| EV / FCF | 7,441 x | 1.45 x | -1.07 x | -2.57 x | 4.89 x | 5.29 x |
| FCF Yield | 0.01% | 68.9% | -93.6% | -38.9% | 20.4% | 18.9% |
| Price to Book | 0.84 x | 0.57 x | 0.29 x | 0.7 x | 1.2 x | 0.84 x |
| Nbr of stocks (in thousands) | 21,041 | 21,041 | 21,041 | 21,041 | 21,041 | 21,041 |
| Reference price 2 | 38.75 | 26.65 | 13.85 | 36.00 | 69.70 | 53.80 |
| Announcement Date | 8/13/18 | 9/4/19 | 9/5/20 | 9/6/21 | 9/3/22 | 9/5/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 628.4 | 779.9 | 859.7 | 975.5 | 1,230 | 929.6 |
| EBITDA 1 | 43.51 | 13.4 | 58.54 | 86.33 | 214.4 | 80.91 |
| EBIT 1 | 32.23 | 2.429 | 47.12 | 74.04 | 197.8 | 67.62 |
| Operating Margin | 5.13% | 0.31% | 5.48% | 7.59% | 16.08% | 7.27% |
| Earnings before Tax (EBT) 1 | 46.3 | 25.38 | 29.08 | 107.9 | 195.6 | 158.9 |
| Net income 1 | 27.9 | 7.939 | 18.53 | 72.47 | 140.9 | 125.8 |
| Net margin | 4.44% | 1.02% | 2.16% | 7.43% | 11.45% | 13.54% |
| EPS 2 | 1.326 | 0.3773 | 0.8809 | 3.444 | 6.697 | 5.980 |
| Free Cash Flow 1 | 0.0651 | 190.3 | 137.8 | -130.2 | 168.1 | 65.56 |
| FCF margin | 0.01% | 24.4% | 16.03% | -13.35% | 13.67% | 7.05% |
| FCF Conversion (EBITDA) | 0.15% | 1,419.66% | 235.35% | - | 78.42% | 81.03% |
| FCF Conversion (Net income) | 0.23% | 2,396.92% | 743.35% | - | 119.32% | 52.1% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/13/18 | 9/4/19 | 9/5/20 | 9/6/21 | 9/3/22 | 9/5/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 331 | 284 | 439 | 423 | 644 | 785 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 0.07 | 190 | 138 | -130 | 168 | 65.6 |
| ROE (net income / shareholders' equity) | 2.9% | 0.81% | 1.86% | 6.97% | 12.3% | 9.82% |
| ROA (Net income/ Total Assets) | 1.63% | 0.13% | 2.43% | 3.54% | 8.37% | 2.62% |
| Assets 1 | 1,711 | 6,346 | 763.3 | 2,049 | 1,685 | 4,801 |
| Book Value Per Share 2 | 46.30 | 46.70 | 47.70 | 51.20 | 57.90 | 64.00 |
| Cash Flow per Share 2 | 0.0900 | 0.0700 | 2.360 | 0.8600 | 0.7500 | 4.190 |
| Capex 1 | 40 | 8.5 | 25.5 | 32.2 | 21.9 | 11.3 |
| Capex / Sales | 6.37% | 1.09% | 2.96% | 3.3% | 1.78% | 1.21% |
| Announcement Date | 8/13/18 | 9/4/19 | 9/5/20 | 9/6/21 | 9/3/22 | 9/5/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -8.03% | 24.35M | |
| +20.22% | 43.67B | |
| +20.67% | 22.51B | |
| +13.34% | 14.6B | |
| +14.14% | 13.74B | |
| +43.51% | 11.91B | |
| -8.37% | 7.04B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.42B |
- Stock Market
- Equities
- ALPA Stock
- Financials Alpa Laboratories Limited
